Corticosteroid Treatment Prevents Lipopolysaccharide-Induced Increase of ACE2 and Reduces Fibrin Degradation Products in Bronchoalveolar Lavage Fluid.
Angiotensin-Converting Enzyme 2
Renin-Angiotensin-Aldosterone System
acute lung injury
fibrin degradation products
randomized controlled trial
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2022
2022
Historique:
received:
17
01
2022
accepted:
01
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
22
3
2022
Statut:
epublish
Résumé
The assessment of systemic corticosteroid effects on intrapulmonary disease biomarkers is challenging. This retrospective evaluation of a human endotoxemia model quantified ACE2 and fibrin degradation product (FDP) concentrations in bronchoalveolar lavage fluid (BALF) samples from a randomized, double-blind, placebo-controlled study (NCT01714427). Twenty-four healthy volunteers received either 2 × 40 mg intravenous dexamethasone or placebo. These doses were administered 12 h apart prior to bronchoscopy-guided intrabronchial lipopolysaccharide (LPS) stimulation (control: saline into the contralateral lung segment). We quantified ACE2 concentration, the Angiotensin-II-to-Angiotensin-1-7 conversion rate as well as FDP in BALF 6 h after LPS instillation. In placebo-treated subjects, LPS instillation increased ACE2 concentrations compared to unstimulated lung segments [1,481 (IQR: 736-1,965) vs. 546 (413-988) pg/mL;
Identifiants
pubmed: 35308535
doi: 10.3389/fmed.2022.856891
pmc: PMC8924661
doi:
Types de publication
Journal Article
Langues
eng
Pagination
856891Subventions
Organisme : Austrian Science Fund FWF
ID : KLI 861
Pays : Austria
Informations de copyright
Copyright © 2022 Reindl-Schwaighofer, Eskandary, Bartko, Heinzel, Jilma, Hecking and Schoergenhofer.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Am J Respir Crit Care Med. 2021 May 1;203(9):1191-1196
pubmed: 33600742
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Thromb Haemost. 2017 Aug 30;117(9):1714-1721
pubmed: 28796276
Crit Care. 2020 Jun 11;24(1):327
pubmed: 32527297
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Nat Genet. 2020 Dec;52(12):1283-1293
pubmed: 33077916
Ann Intern Med. 2020 Sep 1;173(5):350-361
pubmed: 32422076
Elife. 2020 Jul 07;9:
pubmed: 32633718
J Immunol. 2007 Feb 1;178(3):1845-51
pubmed: 17237435
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
Am J Physiol Lung Cell Mol Physiol. 2018 Jan 01;314(1):L17-L31
pubmed: 28935640
Br J Clin Pharmacol. 2016 May;81(5):865-77
pubmed: 26647918
J Thromb Haemost. 2016 Dec;14(12):2471-2477
pubmed: 27622544